<DOC>
	<DOCNO>NCT00073073</DOCNO>
	<brief_summary>The primary goal 5-year study determine whether exemestane alone combination celecoxib decrease breast tissue density healthy postmenopausal woman high risk breast cancer . Dense breast tissue see mammography link increase risk breast cancer . The study also examine effect exemestane celecoxib bone density , blood hormone level quality life . Exemestane , approve Food Drug Administration treat postmenopausal woman breast cancer , lower amount estrogen body . Celecoxib , approve treat arthritis pain reduce number colon polyp inherit syndrome , anti-inflammatory drug . Half woman study receive exemestane alone half receive exemestane celecoxib together . In December 2004 , arm use exemestane celecoxib close accrual Postmenopausal woman increase risk develop invasive breast cancer may eligible participate . Candidates screen breast cancer risk assessment , medical history physical examination , blood test , review medical record , need , breast biopsy , dual energy x-ray absorptiometry ( DEXA ) scan ass bone density . For DEXA scan , subject lie still table 30 minute spine hip scan use small amount radiation . Participants take exemestane pill form day 2 year . They also take calcium vitamin D pills daily help protect bone health . They follow clinic course study determine amount drug take side effect , follow test procedure : - Medical evaluation blood test 1 3 month study drug - Medical evaluation 6 month - Breast biopsy screen 12 month - dual-emission x-ray absorptiometry ( DEXA ) scan spine , mammogram routine blood test start study drug yearly 5 year .</brief_summary>
	<brief_title>Exemestane Celecoxib Postmenopausal Women High Risk Breast Cancer</brief_title>
	<detailed_description>Background : Evidence adjuvant treatment trial invasive breast cancer aromatase inhibitor suggest agent superior tamoxifen prevent contralateral breast cancer well tolerate . These agent promise breast cancer chemopreventive agent . Data safety effect surrogate biomarkers healthy risk population lack . Objectives : Primary : -The primary objective evaluate study drug effect mammographic density one year treatment . Secondary : -Secondary objective include assess effect intervention bone mineral density , serum hormone lipid , breast tissue biomarkers . Eligibility : Eligible patient postmenopausal woman meet one follow criterion : - History stage I II breast cancer 2 year definitive therapy . - Gail model 5 year risk great equal 1.7 % - History treat ductal carcinoma in-situ ( DCIS ) - History high risk lesion breast biopsy ( atypical ductal hyperplasia ( ADH ) , atypical lobular hyperplasia ( ALH ) , lobular carcinoma in-situ ( LCIS ) ) - Known suspected breast cancer 1 , early onset ( BRCA1 ) breast cancer 2 , early onset ( BRCA2 ) mutation - Subjects must adequate bone mineral density dual-emission x-ray absorptiometry ( DEXA ) scan order enroll . Design : - This open label study exemestane postmenopausal woman elevate risk develop invasive breast cancer . Forty five subject enrol receive standard dose exemestane ( 25 mg day ( QD ) ) , calcium vitamin D. - Each subject continue treatment total two year . - Changes mammographic breast density bone mineral density evaluate annually provide long term biomarker safety information prevention therapy exemestane .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>INCLUSION CRITERIA : Postmenopausal female . Postmenopausal define menses least 12 month bilateral oophorectomy . In unclear case , ( e.g . 50 year old hysterectomy ) chemical confirmation postmenopausal status may confirm follicle stimulate hormone ( FSH ) great 35 U/L . Elevated risk develop invasive breast cancer virtue one follow criterion : Gail Model risk great equal 1.7 % 5 year study entry . ( This minimum level risk require subject eligible recently complete NSABPP1 tamoxifen breast cancer prevention trial ) . Lobular neoplasia . Atypical ductal hyperplasia . DCIS ( ductal carcinoma situ ) previously treat mastectomy lumpectomy radiation , +/ tamoxifen . Deleterious mutation BRCA1 2 OR A priori risk assessment 20 % chance great carry BRCA1/2 gene mutation . The BRCAPRO Couch model use ass risk . If woman 20 % risk carry BRCA1/2 mutation either model , meet eligibility criterion . Prior stage I II breast cancer least 2 year treatment invasive disease prior use aromatase inhibitor . Subjects willing abstain use hormonal therapy ( e.g . tamoxifen , hormone replacement therapy , oral contraceptive pill , hormonecontaining intrauterine device ( IUDs ) . Estring acceptable ) . Venlafaxine offer supportive care woman menopausal symptom . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . Subject counsel regard option sign informed consent document . Baseline dualemission xray absorptiometry ( DEXA ) scan bone mineral density ( BMD ) Tscore great equal 2.5 antero posterior ( AP ) spine . Hemoglobin great equal 11 g/dl . Creatinine le 1.5 time upper limit normal . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) less 2.5 time upper limit normal . No investigational agent past 30 day . If history cancer ( squamous basal cell skin cancer ) , subject must evidence disease time enrollment AND history cancer direct treatment 2 year precede enrollment . EXCLUSION CRITERIA : Current recent chronic use ( within 3 month ) hormonal medication , e.g . oral contraceptive pill , hormone replacement therapy , tamoxifen , raloxifene , IUD progestins corticosteroid . ( Subjects chronic topical inhale steroid eligible study . ) Current use phenytoin , carbamazepine , rifampin due increase estrogen metabolism . History clot bleed disorder . History allergic reaction attribute compound similar chemical biologic composition exemestane ( e.g . anastrozole , letrozole , formestane ) . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Chemoprevention</keyword>
	<keyword>Mammographic Density</keyword>
	<keyword>Bone Mineral Density</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Safety</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Postmenopausal</keyword>
</DOC>